SCHEMBL14949320

SCHEMBL14949320

Cc1cccc(Nc2nnc(-c3cccc(Oc4cc(N)nc(N)n4)c3)o2)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.42
SMN1; SMN2 Q16637 6/20 0.41
NPC1 O15118 6/20 0.41
RAB9A P51151 6/20 0.41
TP53 P04637 5/20 0.41
KMT2A Q03164 5/20 0.41
MEN1 O00255 4/20 0.41
MAPK1 P28482 2/20 0.41
GSK3B P49841 3/20 0.40
HPGD P15428 4/20 0.40
ALDH1A1 P00352 3/20 0.40
HSD17B10 Q99714 2/20 0.40
POLB P06746 1/20 0.40
FLT1 P17948 3/20 0.39
KDR P35968 3/20 0.39
FLT4 P35916 1/20 0.39
TSHR P16473 1/20 0.38
MAPT P10636 3/20 0.37
GLA P06280 1/20 0.37
GAA P10253 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14949329 0.92 KDM4E (0.42) KDM4ESMN1; SMN2NPC1RAB9ATP53
SCHEMBL14949328 0.92 KDM4E (0.42) KDM4ESMN1; SMN2NPC1RAB9ATP53
SCHEMBL12057527 0.91 NPC1 (0.47) KDM4ESMN1; SMN2NPC1RAB9ATP53
SCHEMBL17658729 0.90 KDM4E (0.42) KDM4ESMN1; SMN2NPC1RAB9ATP53
SCHEMBL16786023 0.87 KDM4E (0.39) KDM4ESMN1; SMN2NPC1RAB9ATP53
SCHEMBL12336259 0.87 GSK3B (0.45) KDM4ESMN1; SMN2NPC1RAB9AGSK3B
SCHEMBL17662111 0.82 GSK3B (0.43) KDM4ESMN1; SMN2NPC1RAB9ATP53
SCHEMBL14949323 0.82 KDR (0.44) KDM4ESMN1; SMN2NPC1RAB9ATP53
SCHEMBL14949499 0.81 PDGFRB (0.44) KDM4ESMN1; SMN2NPC1RAB9ATP53
SCHEMBL17658728 0.81 KDM4E (0.44) KDM4ESMN1; SMN2NPC1RAB9ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160096824-A1 Heterocyclic Compounds Useful for Kinase Inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. 2016-04-07 US disclosed
US-9212151-B2 Heterocyclic compounds useful for kinase inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. (US) 2015-12-15 US disclosed
US-20150158828-A1 Heterocyclic Compounds Useful for Kinase Inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. 2015-06-11 US disclosed
US-8957216-B2 Heterocyclic compounds useful for kinase inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. (US) 2015-02-17 US disclosed
US-20130123284-A1 HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION AMITECH THERAPEUTIC SOLUTIONS INC (US) 2013-05-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130123284-A1 HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION MAP4K2, MAP3K20, MAP3K19 KDM4E 1098/4885SMN1; SMN2 4181/4885NPC1 3866/4885
US-20150158828-A1 Heterocyclic Compounds Useful for Kinase Inhibition MAP4K2, MAP3K20, MAP3K19 KDM4E 1098/4885SMN1; SMN2 4181/4885NPC1 3866/4885
US-20160096824-A1 Heterocyclic Compounds Useful for Kinase Inhibition MAP4K2, MAP3K20, MAP3K19 KDM4E 1098/4885SMN1; SMN2 4181/4885NPC1 3866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.